EXEL
EXELIXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$70.22
−0.69%Income statement
| Metric | TTM | 2026 | 2025 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5B | 2.3B | 2.2B | 1.8B | 1.6B |
| Cost of Revenue | 93.3M | 83.7M | 76.2M | 72.5M | 57.9M |
| Gross Profit | 2.4B | 2.2B | 2.1B | 1.8B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 834.6M | 825.0M | 910.4M | 1.0B | 891.8M |
| SG&A Expense | 564.8M | 518.7M | 492.1M | 542.7M | 459.9M |
| General & Admin Expense | 513.1M | 467.0M | 492.1M | 502.7M | 418.3M |
| Selling & Marketing Expense | 51.7M | 51.7M | — | 40.0M | 41.6M |
| Other Expenses | 694.0K | 20.5M | 85.3M | 1.00 | (197.0K) |
| Total Operating Expenses | 1.4B | 1.4B | 1.5B | 1.6B | 1.4B |
| Cost and Expenses | 1.5B | 1.4B | 1.6B | 1.7B | 1.4B |
| Operating Income (EBIT) | 1.0B | 872.2M | 604.6M | 170.9M | 201.5M |
| Non-Operating | |||||
| Interest Income | 62.1M | 69.2M | 77.2M | 86.5M | 33.1M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 62.1M | 69.2M | 77.2M | 86.5M | 33.1M |
| Other Non-Op Income/Expense | 62.4M | 69.0M | 77.0M | 86.6M | 32.9M |
| Non-Operating Income (excl Interest) | (45.7M) | (20.5M) | (85.3M) | (86.6M) | (32.9M) |
| EBT (Pre-Tax Income) | 1.1B | 941.2M | 681.6M | 257.5M | 234.4M |
| Income Tax Expense | 180.7M | 158.6M | 160.4M | 49.8M | 52.1M |
| Bottom Line | |||||
| Net Income | 885.1M | 782.6M | 521.3M | 207.8M | 182.3M |
| Earnings from Cont. Ops | 885.1M | 782.6M | 521.3M | 207.8M | 182.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 885.1M | 782.6M | 521.3M | 207.8M | 182.3M |
| Per Share | |||||
| Basic EPS | $3.45 | $2.88 | $1.80 | $0.65 | $0.57 |
| Diluted EPS | $3.34 | $2.78 | $1.76 | $0.65 | $0.56 |
| Revenue Per Share | $10.12 | $8.54 | $7.48 | $5.75 | $5.01 |
| Shares | |||||
| Basic Shares Outstanding | 246.8M | 271.6M | 290.0M | 318.2M | 321.5M |
| Diluted Shares Outstanding | 255.8M | 281.9M | 296.1M | 321.5M | 324.6M |
| Profitability Metrics | |||||
| EBITDA | 1.1B | 921.8M | 718.8M | 283.2M | 255.2M |
| D&A | 27.8M | 29.1M | 28.8M | 25.7M | 20.9M |
| EBIT | 1.0B | 892.7M | 689.9M | 257.5M | 234.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Oct 1, 2026